-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
ProQR Therapeutics (NASDAQ:PRQR) Forecasted to Post FY2022 Earnings of ($0.77) Per Share
ProQR Therapeutics (NASDAQ:PRQR) Forecasted to Post FY2022 Earnings of ($0.77) Per Share
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) – Cantor Fitzgerald lifted their FY2022 EPS estimates for ProQR Therapeutics in a research note issued to investors on Monday, August 15th. Cantor Fitzgerald analyst J. Kim now forecasts that the biopharmaceutical company will post earnings per share of ($0.77) for the year, up from their prior forecast of ($0.84). Cantor Fitzgerald currently has a "Neutral" rating on the stock. The consensus estimate for ProQR Therapeutics' current full-year earnings is ($0.83) per share. Cantor Fitzgerald also issued estimates for ProQR Therapeutics' FY2023 earnings at ($0.62) EPS.
Get ProQR Therapeutics alerts:A number of other brokerages have also recently weighed in on PRQR. HC Wainwright dropped their price target on shares of ProQR Therapeutics from $4.00 to $2.00 in a research report on Monday, May 9th. Raymond James raised shares of ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 price objective for the company in a research note on Friday, August 12th. Chardan Capital lowered shares of ProQR Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, August 12th. Finally, StockNews.com raised shares of ProQR Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, May 9th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $5.00.
ProQR Therapeutics Price Performance
Shares of PRQR opened at $0.85 on Wednesday. ProQR Therapeutics has a 1-year low of $0.53 and a 1-year high of $9.09. The stock has a market cap of $60.60 million, a PE ratio of -0.85 and a beta of 0.80. The firm has a 50-day simple moving average of $0.80 and a two-hundred day simple moving average of $1.14. The company has a debt-to-equity ratio of 0.43, a current ratio of 5.93 and a quick ratio of 5.93.Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in shares of ProQR Therapeutics during the 2nd quarter worth approximately $48,000. ProShare Advisors LLC purchased a new stake in shares of ProQR Therapeutics during the 4th quarter worth approximately $80,000. Monaco Asset Management SAM purchased a new stake in shares of ProQR Therapeutics during the 1st quarter worth approximately $82,000. Coastal Bridge Advisors LLC purchased a new stake in shares of ProQR Therapeutics during the 4th quarter worth approximately $85,000. Finally, Daiwa Securities Group Inc. lifted its position in shares of ProQR Therapeutics by 22.1% during the 4th quarter. Daiwa Securities Group Inc. now owns 13,017 shares of the biopharmaceutical company's stock worth $104,000 after buying an additional 2,352 shares during the last quarter.
ProQR Therapeutics Company Profile
(Get Rating)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
See Also
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- Which Semiconductor Stocks Are Ready For Big Price Moves?
- Miners Advance On Earnings Despite Broader Economic Challenges
- Lowe's Stands Out Amid Q2 Retail Reports
- Agilent Technologies Proves Its Worth VS Illumina
- Target's Results Cap Upside Potential For Retail Stocks
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) – Cantor Fitzgerald lifted their FY2022 EPS estimates for ProQR Therapeutics in a research note issued to investors on Monday, August 15th. Cantor Fitzgerald analyst J. Kim now forecasts that the biopharmaceutical company will post earnings per share of ($0.77) for the year, up from their prior forecast of ($0.84). Cantor Fitzgerald currently has a "Neutral" rating on the stock. The consensus estimate for ProQR Therapeutics' current full-year earnings is ($0.83) per share. Cantor Fitzgerald also issued estimates for ProQR Therapeutics' FY2023 earnings at ($0.62) EPS.
ProQR治療公司(納斯達克:PRQR-GET評級)--坎託·菲茨傑拉德在8月15日星期一發給投資者的一份研究報告中上調了他們對ProQR治療公司2022財年每股收益的估計。Cantor Fitzgerald分析師J.Kim現在預測,這家生物製藥公司今年的每股收益將為0.77美元,高於此前預測的0.84美元。康託·菲茨傑拉德目前對該股的評級為“中性”。對ProQR治療公司目前全年收益的普遍估計為每股0.83美元。Cantor Fitzgerald還發布了對ProQR治療公司2023財年每股收益的估計為(0.62美元)。
A number of other brokerages have also recently weighed in on PRQR. HC Wainwright dropped their price target on shares of ProQR Therapeutics from $4.00 to $2.00 in a research report on Monday, May 9th. Raymond James raised shares of ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 price objective for the company in a research note on Friday, August 12th. Chardan Capital lowered shares of ProQR Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, August 12th. Finally, StockNews.com raised shares of ProQR Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, May 9th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $5.00.
其他一些券商最近也加入了PRQR的行列。在5月9日星期一的一份研究報告中,HC Wainwright將ProQR治療公司的股票目標價從4.00美元下調至2.00美元。雷蒙德·詹姆斯在8月12日星期五的一份研究報告中將ProQR治療公司的股票從“市場表現”評級上調至“跑贏大盤”評級,併為該公司設定了2.00美元的價格目標。Chardan Capital在8月12日星期五的一份研究報告中將ProQR治療公司的股票評級從“買入”下調至“中性”。最後,StockNews.com在5月9日星期一的一份研究報告中將ProQR治療公司的股票從“賣出”評級上調為“持有”評級。五位分析師對該股的評級為持有,四位分析師對該公司股票的評級為買入。根據MarketBeat的數據,該公司目前的普遍評級為持有,平均目標價為5.00美元。
ProQR Therapeutics Price Performance
ProQR治療藥物性價比
Institutional Inflows and Outflows
機構資金流入和流出
A number of institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in shares of ProQR Therapeutics during the 2nd quarter worth approximately $48,000. ProShare Advisors LLC purchased a new stake in shares of ProQR Therapeutics during the 4th quarter worth approximately $80,000. Monaco Asset Management SAM purchased a new stake in shares of ProQR Therapeutics during the 1st quarter worth approximately $82,000. Coastal Bridge Advisors LLC purchased a new stake in shares of ProQR Therapeutics during the 4th quarter worth approximately $85,000. Finally, Daiwa Securities Group Inc. lifted its position in shares of ProQR Therapeutics by 22.1% during the 4th quarter. Daiwa Securities Group Inc. now owns 13,017 shares of the biopharmaceutical company's stock worth $104,000 after buying an additional 2,352 shares during the last quarter.
一些機構投資者最近增持或減持了該公司的股份。Virtu Financial LLC在第二季度購買了ProQR治療公司的新股份,價值約4.8萬美元。ProShare Advisors LLC在第四季度購買了ProQR治療公司的新股份,價值約8萬美元。摩納哥資產管理公司SAM在第一季度購買了ProQR治療公司的新股份,價值約82,000美元。Coastate Bridge Advisors LLC在第四季度購買了ProQR治療公司價值約8.5萬美元的新股份。最後,大和證券集團在第四季度將其持有的ProQR治療公司股票的倉位提高了22.1%。大和證券集團(Daiwa Securities Group Inc.)目前持有這家生物製藥公司13,017股股票,價值10.4萬美元,該公司在上個季度又購買了2,352股。
ProQR Therapeutics Company Profile
ProQR治療公司簡介
(Get Rating)
(獲取評級)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
ProQR Treateutics N.V.是一家生物製藥公司,致力於發現和開發基於RNA的治療遺傳疾病的療法。它主要開發正處於II/III期臨牀試驗的sepofarsen,用於治療Leber先天性黑髮10病的照明試驗;以及正在進行II/III期臨牀試驗的ultevursen,用於治療USH2A介導的視網膜色素變性和USHER綜合徵。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- Which Semiconductor Stocks Are Ready For Big Price Moves?
- Miners Advance On Earnings Despite Broader Economic Challenges
- Lowe's Stands Out Amid Q2 Retail Reports
- Agilent Technologies Proves Its Worth VS Illumina
- Target's Results Cap Upside Potential For Retail Stocks
- 免費獲取StockNews.com關於ProQR治療(PRQR)的研究報告
- 哪些半導體類股準備好迎接價格大幅波動?
- 儘管面臨更廣泛的經濟挑戰,礦商的收益仍在上漲
- Lowe‘s在第二季度零售報告中脱穎而出
- 安捷倫科技對Illumina證明瞭自己的價值
- 塔吉特的業績上限零售類股的上行潛力
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受ProQR治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對ProQR治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧